The talk of the town at this year’s American Society of Addiction Medicine annual conference was GLP-1 receptor agonists, generally known as medications to treat obesity. Mainstream media appears to mirror this trend as nearly every other radio and television ad seemingly involves a weight loss medication. In addition to treating obesity and Type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD). Because so many questions exist about safety, efficacy, long-term effects and more, ASAM appropriately invited several scientists and clinicians to present the latest data on the role of GLP-1 RAs in addiction.
CDC To Clinicians: Look Out for Medetomidine in Opioid Overdose
Clinicians should be on alert for signs of medetomidine exposure and withdrawal in suspected overdose cases, public...
0 Comments